SCHEMBL5651076

SCHEMBL5651076

CN1CCN(CCCNC(=O)c2sc3c(ccc(=O)n3-c3ccccc3)c2-c2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.47
DRD2 P14416 2/20 0.46
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
HSD17B10 Q99714 3/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
MAPK1 P28482 1/20 0.45
MEN1 O00255 1/20 0.45
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
PARP1 P09874 1/20 0.44
TP53 P04637 2/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
AHR P35869 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652071 0.90 HTT (0.51) KDM4EALDH1A1HSD17B10KMT2AMAPT
SCHEMBL2953704 0.87 MAPT (0.46) DRD2KDM4EALDH1A1HSD17B10KMT2A
SCHEMBL5653732 0.87 PARP1 (0.47) KDM4EALDH1A1HSD17B10KMT2AMAPT
SCHEMBL5651037 0.86 PARP1 (0.46) KDM4EALDH1A1HSD17B10KMT2AMAPT
SCHEMBL5654415 0.85 HIF1A (0.38) KDM4EALDH1A1HSD17B10KMT2AMAPT
SCHEMBL5652540 0.84 HPGD (0.52) KDM4EALDH1A1KMT2AMAPTHPGD
SCHEMBL5652095 0.82 HPGD (0.45) KDM4EALDH1A1HSD17B10KMT2AMAPT
SCHEMBL5649437 0.81 HPGD (0.44) KDM4EALDH1A1KMT2AMAPTHPGD
SCHEMBL5652559 0.80 SMN1; SMN2 (0.52) KDM4EALDH1A1HSD17B10KMT2AHPGD
SCHEMBL5648449 0.80 ALDH1A1 (0.51) KDM4EALDH1A1HSD17B10KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 BCL2L1 733/4885DRD2 1936/4885KDM4E 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.